Showing 1-5 of 47 :
Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care

American Journal of Managed Care Mar 17, 2023 Christina Mattina Read the Full Article >> Speakers at the American Academy of Dermatology 2023 Annual Meeting highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to[…]

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

Dermatology Times Mar 19, 2023 Kaitlyn Bader Read the Full Article >>   A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA. There is a lack of evidence investigating the impact of patient-reported outcomes (PROs) monitoring in routine clinical practice, according to a[…]

Interview with OM1’s Jessica Paulus at SCOPE

Published on: March 9, 2023 Applied Clinical Trials Watch the Full Interview >> Key Learning Objectives: Challenges people encounter when working with RWD How can RWD help address gaps in care? How OM1 engages or supports health equity research using RWD

Hard to Define, Harder to Find Patients: Using AI & Real-World Data to Understand Treatment Resistant Depression

Published March 13, 2023 from Read the full article >> Mental health conditions can take a staggering toll on an individual physically, socially and financially. Many patients languish with partially effective or ineffective treatments, even though new options are constantly entering the market. At OM1, we are using our extensive mental health data network[…]

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder

Published: February 14, 2022 BMC Psychiatry Read the Full Article >> Background: Many second-generation antipsychotics (SGAs) are associated with weight gain and cardiometabolic effects. Antipsychotic-associated weight gain is linked to treatment interruptions, potentially increasing risk of relapse and hospitalization. This retrospective study assessed clinically significant weight gain (CSWG), treatment interruptions, and development of cardiometabolic conditions[…]

1 2 3 10